Ripple Therapeutics secures Licensing Agreement and Series A Financing led by Théa Open Innovation

Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel therapeutics, announced the signing of an exclusive Licensing Agreement for the rights to their lead product, IBE-814, for North America and Europe with Théa Open Innovation ("TOI") a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. In addition to the Licensing Agreement, Ripple announced that TOI is leading their Series A Financing.